InvestBio Portfolio Company
Presents Phase I/II Trial Results of Vaccine for Leukemia at American
Society of Hematology Annual Meeting
To Date, InvestBio has Raised $20 Million for The Vaccine Company
(TVC); TVC Now in Phase III Trials
NEW YORK (Business Wire EON/PRWEB ) February 29, 2008 --
Results from a clinical study using technology licensed by The
Vaccine Company (TVC), an InvestBio,
Inc. portfolio company, were presented at the 49th
Annual Meeting of the American Society of Hematology.
The company’s PR1 peptide vaccine is derived
from two proteins that are either overexpressed or aberrantly expressed
in certain cancer cells. Administration of the PR1 vaccine to some
patients elicits the proliferation of, PR1-specific cytotoxic T
lymphocytes that selectively kill three types of leukemia -
myelodysplastic syndrome, acute myelogenous leukemia and chronic
myelogenous leukemia.
In the Phase I/II study, the median time in remission for leukemia
patients who responded to the PR1 vaccine was three times longer than
for non-responders. The Phase I/II clinical trial ran from 2000 to 2006
and was designed to assess the vaccine’s
safety and ability to elicit an immune response. TVC is now conducting a
Pivotal Phase III clinical trial with the vaccine to treat acute
myelogenous leukemia.
The PR1 vaccine was developed by Jeffrey Molldrem, M.D., professor at
The University of Texas M.D. Anderson Cancer Center. Dr. Molldrem
co-founded TVC in 2003, and the company licensed the technology from
M.D. Anderson in 2004. M.D. Anderson has an equity interest in TVC.
“Dr. Molldrem’s
positive results with the PR1 vaccine as reported at ASH gave us
confidence to invest in follow-on Phase III and Phase II clinical trials
of the vaccine. Early results are validating that confidence,”
said Gregory Thayer, President & CEO of The Vaccine Company. “We’re
delighted by the responses that The Vaccine Company was able to present,”
said Scott Mathis, founder and head of InvestBio and its parent
company, Diversified Private Equity Corp. (DPEC
Partners). InvestBio
creates opportunities for accredited investors to participate in private
equity investments in promising biotech companies. InvestBio has raised
$20 million for TVC. Mr. Mathis serves on the TVC board of directors.
For more information, please contact Alexandra Corriveau at
Sommerfield Communications, Inc. at 212-255-8386 or alexandra@sommerfield.com.
About InvestBio and DPEC
Partners
InvestBio, Inc., is a subsidiary of Diversified Private Equity Corp. (DPEC
Partners) that focuses on identifying and forming investment
vehicles that enable accredited investors to participate in private
equity investments in promising biotech companies. DPEC
Partners is an integrated company whose businesses bring
entrepreneurial, private equity and institutional-quality investments to
accredited investors in the U.S.
About The Vaccine Company
The Vaccine Company, a Delaware corporation formed in 2003, was founded
to commercialize the PR1 vaccine developed at the M.D. Anderson Cancer
Center at the University of Texas. The Vaccine Company has an exclusive
worldwide license from the M.D. Anderson Cancer Center. The license
includes exclusive rights to other potential peptide vaccines, which the
company intends to advance to clinical trials.
See the original story at: http://eon.businesswire.com/releases/vaccine/company/prweb733414.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/SW5zZS1DcmFzLUVtcHQtUGlnZy1Ib3JyLVplcm8=
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
